预防性治疗可以改变高频发作和慢性偏头痛患者的血管风险生物标志物:试点研究
Cristina González Mingot1,2, Sonia Santos Lasaosa3, Laura Colàs Campàs4
1Neuroimmunology Group, Department of Medicine, University of Lleida (UdL)-IRBLleida, Alcalde Rovira Roure 80, 25198, Lleida, Spain. cristina.gonzalez@udl.cat.
Scientific reports
|November 8, 2023
概括
偏头痛的预防性治疗,包括高频和慢性类型,可以改善内皮和氧化生物标志物,表明血管疾病风险降低. 这项试点研究表明,治疗对偏头痛患者的关键标志物产生积极影响.
科学领域:
- 神经学 神经学
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛与内皮和氧化功能障碍有关,这是血管疾病的潜在风险因素.
- 高频发作性和慢性偏头痛可能与对照组相比呈现出更大的生物标记差异.
研究的目的:
- 调查预防性治疗是否会改变偏头痛患者的内皮和氧化生物标志物.
- 为了评估在3个月的metoprolol或topiramate治疗后血管疾病风险标志物的变化.
主要方法:
- 观察性,前性试点研究,涉及88名偏头痛患者和56名对照人群.
- 基线和治疗后的超声波和血液测试分析了诸如hsCRP,vWF,酸盐和异质这样的生物标志物.
- 患者根据偏头痛的频率和对预防性治疗的反应进行了分类.
主要成果:
- 偏头痛患者,特别是患有高频或慢性偏头痛的患者,与对照人群相比,hsCRP,vWF抗原/活性和异质水平存在显著差异.
- 治疗反应者在治疗后呈现酸盐和酸盐的增加.
- 响应的患者显示hsCRP,vWF活性和前热血素活性下降,表明内皮和氧化状态有所改善.
结论:
- 偏头痛与内皮和氧化功能障碍有关,在高频和慢性偏头痛中影响更为明显.
- 预防性治疗有效地改变了这些生物标志物,这表明血管疾病风险的潜在降低.
- 这些发现支持预防性治疗在管理偏头痛血管方面的作用.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
133
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
133
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:19Mitral Valve Prolapse III: Nursing Management
14
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
14
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
864
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
864
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535